Clinics in Endocrinology and Metabolism最新文献_第3页

8 Growth hormone releasing hormone 8生长激素释放激素

Clinics in Endocrinology and Metabolism Pub Date : 1986-08-01 DOI: 10.1016/S0300-595X(86)80012-3

Ashley Grossman M.O., Savage G.M. Besser

{"title":"8 Growth hormone releasing hormone","authors":"Ashley Grossman M.O., Savage G.M. Besser","doi":"10.1016/S0300-595X(86)80012-3","DOIUrl":"10.1016/S0300-595X(86)80012-3","url":null,"abstract":"<div>Human growth hormone releasing hormone (GHRH) was originally extracted from two pancreatic tumours in patients with acromegaly, and is now known to consist of a 44 residue amidated peptide or its C-terminal-shortened derivatives. The sequence of rat GHRH has also been determined; this 43 residue peptide shows approximately 70% homology with human GHRH, and is located mainly in the arcuate nucleus of the hypothalamus. Pulsatile GH release in the rat is principally a consequence of the pulsatile release of hypothalamic GHRH, although this appears to be associated with a transient suppression of somatostatin release. Exogenous GHRH specifically increases circulating GH in many species, and in the long term may increase growth.In normal man, several analogues of GHRH have been shown to be safe, sensitive and specific stimuli to GH release; although there may be a variable prolactin response, this is usually of small magnitude. Continuous infusion of GHRH leads to a decrement in responsiveness, due at least in part to changes in hypothalamic somatostatin. The GH response to GHRH is also modulated by obesity, blood sugar, free fatty acids, and GH itself. Many children with ‘GH deficiency’ (idiopathic, radiation-induced, or secondary to hypothalamopituitary tumours) respond to intravenous GHRH with an acute rise in serum GH.Early studies also indicate that long-term therapy with subcutaneous GHRH may increase growth velocity in some of these children. It is concluded that analogues of GHRH are useful in the investigation of the hypothalamopituitary axis, and may be important in the therapy of short stature.</div>","PeriodicalId":10454,"journal":{"name":"Clinics in Endocrinology and Metabolism","volume":"15 3","pages":"Pages 607-627"},"PeriodicalIF":0.0,"publicationDate":"1986-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0300-595X(86)80012-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13575506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

2 The growth of children with chronic paediatric disease 慢性儿科疾病患儿的生长发育

Clinics in Endocrinology and Metabolism Pub Date : 1986-08-01 DOI: 10.1016/S0300-595X(86)80006-8

M.A. Preece, C.M. Law, P.S.W. Davies

引用次数: 49

3 Clinical features and investigation of growth hormone deficiency 3生长激素缺乏症的临床特点及探讨

Clinics in Endocrinology and Metabolism Pub Date : 1986-08-01 DOI: 10.1016/S0300-595X(86)80007-X

C.G.D. Brook, P.C. Hindmarsh, P.J. Smith, R. Stanhope

引用次数: 17

9 Somatomedin-C/insulin-like growth factor I in acromegaly 生长因子c /胰岛素样生长因子I在肢端肥大症中的作用

Clinics in Endocrinology and Metabolism Pub Date : 1986-08-01 DOI: 10.1016/S0300-595X(86)80013-5

David R. Clemmons, Louis E. Underwood

引用次数: 20

Index 指数

Clinics in Endocrinology and Metabolism Pub Date : 1986-08-01 DOI: 10.1016/S0300-595X(86)80016-0

引用次数: 0

10 Pathology of excessive production of growth hormone 生长激素过量产生的病理学

Clinics in Endocrinology and Metabolism Pub Date : 1986-08-01 DOI: 10.1016/S0300-595X(86)80014-7

B.W. Scheithauer, K. Kovacs, R.V. Randall, E. Horvath, E.R. Laws Jr

{"title":"10 Pathology of excessive production of growth hormone","authors":"B.W. Scheithauer, K. Kovacs, R.V. Randall, E. Horvath, E.R. Laws Jr","doi":"10.1016/S0300-595X(86)80014-7","DOIUrl":"10.1016/S0300-595X(86)80014-7","url":null,"abstract":"<div>Since its clinical description in the last century, much progress has been made in our understanding of acromegaly. From an initial description of pituitary enlargement as just another manifestation of generalized visceromegaly, the pituitary abnormality has come to be recognized, in most instances, as the underlying aetiological factor. Gigantism and acromegaly are manifestations of disordered pituitary physiology, but the lesion responsible may be hypothalamic, adenohypophyseal or ectopic in location.The best known pathological hypothalamic basis for acromegaly is represented by a neuronal malformation or ‘gangliocytoma’. It usually takes the form of an intrasellar gangliocytoma or, more rarely, a hypothalamic hamartoma. The neuronal elaboration of GHRH may play a role in the development of a growth hormone adenoma; the pituitary process may pass through an intermediate stage of somatotropic hyperplasia.When acromegaly has its basis in a pituitary abnormality, the lesion is almost exclusively an adenoma; the non-tumorous adenohypophysis shows no evidence of coexistent hyperplasia. Surprisingly, such tumours are more often engaged in the formation of multiple hormones rather than GH alone. They frequently produce not only GH and prolactin, the products characteristic of cells of the acidophil line, but also glycoprotein hormones, usually TSH. The spectrum of adenomas also varies in its degree of differentiation from a histogenetically primitive lesion, the acidophil stem cell adenoma, to well-differentiated tumours of varying cellular composition and hormone content. Each adenoma type has its clinicopathological, histochemical, immunocytological and ultrastructural characteristics.The isolation and characterization of GHRH has permitted the identification of neuroendocrine tumours, most of foregut origin, elaborating this releasing hormone. Such functional tumours induce hyperplasia of pituitary somatotrophs and may, on occasion, result in the formation of growth hormone adenomas. Resection of these GHRH-producing neoplasms results in reversal of endocrinological and sellar abnormalities.Future efforts should be directed toward the elucidation of the aetiology of pituitary adenomas, specifically whether they represent a proliferative a hypothalamic abnormality, or whether it has a ‘de novo’ origin in the ‘usual process of neoplastic transformation’.</div>","PeriodicalId":10454,"journal":{"name":"Clinics in Endocrinology and Metabolism","volume":"15 3","pages":"Pages 655-681"},"PeriodicalIF":0.0,"publicationDate":"1986-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0300-595X(86)80014-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14226895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 40

4 Treatment of growth hormone deficiency 4生长激素缺乏症的治疗

Clinics in Endocrinology and Metabolism Pub Date : 1986-08-01 DOI: 10.1016/S0300-595X(86)80008-1

M.B. Ranke, J.R. Bierich

{"title":"4 Treatment of growth hormone deficiency","authors":"M.B. Ranke, J.R. Bierich","doi":"10.1016/S0300-595X(86)80008-1","DOIUrl":"10.1016/S0300-595X(86)80008-1","url":null,"abstract":"<div>According to the results reported in the literature and from our own experience, the following recommendations for the treatment of children with GHD can be given:<ul><li>1.In order to start GH replacement therapy in early childhood the diagnosis of GHD should be made as early as possible.</li><li>2.The growth hormone dose during prepubertal age should not fall short of 12 IU/m2 per week. During spontaneous or induced puberty, the dose needs to be increased, possibly by a factor of two. Daily subcutaneous injections appear most suitable. Treatment with growth hormone releasing factors in cases with hypothalamic GHD, although a promising alternative to the treatment with hGH (Thorner et al, 1985), must be considered experimental at this point.</li><li>3.Thyroxine replacement at a daily dose of 75–100 μg/m2 should be given in cases of secondary hypothyroidism.</li><li>4.Glucocorticoid replacement, if required, should be given at low doses (e.g. hydrocortisone 10 (to 15) mg/m2 per day in divided doses).</li><li>5.In cases with additional gonadotropin deficiency, sex steroids (or anabolic steroids) should be given with frequent monitoring of bone maturity not before the age of 13 in girls or 15 years in boys. In boys depot testosterone starting at low doses (e.g. 50–100 mg/month i.m.) will induce a puberty-like increment in height velocity. Since the effect of oestrogens—even in low doses—on growth is uncertain, their administration before achievement of near-normal adult height should be avoided.</li></ul>With the advancement of diagnostic techniques and with the experience in treatment accumulated over the past 25 years, patients with GHD need no longer become dwarfs.</div>","PeriodicalId":10454,"journal":{"name":"Clinics in Endocrinology and Metabolism","volume":"15 3","pages":"Pages 495-510"},"PeriodicalIF":0.0,"publicationDate":"1986-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0300-595X(86)80008-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13576908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 20

5 Recombinant human growth hormone 5重组人生长激素

Clinics in Endocrinology and Metabolism Pub Date : 1986-08-01 DOI: 10.1016/S0300-595X(86)80009-3

L.M. Fryklund, J.R. Bierich, M.B. Ranke

{"title":"5 Recombinant human growth hormone","authors":"L.M. Fryklund, J.R. Bierich, M.B. Ranke","doi":"10.1016/S0300-595X(86)80009-3","DOIUrl":"10.1016/S0300-595X(86)80009-3","url":null,"abstract":"<div><ul><li>1.All batches of Met-hGH examined stimulated statural growth to approximately the same extent. The growth rates measured partly exceeded the results obtained in previous studies with pituitary preparations in the same dosage.</li><li>2.Under treatment with SI, i.e. the preparation with the highest amount of ECP, high antibody titres with high binding capacity against GH and ECP were found. With SII all antibody determinations showed much lower titres. With Somatonorm (SIII), in the large majority of cases no antibodies were detectable. The titres registered in a few children were low and the binding capacities were negligible.</li><li>3.The biologically determined somatomedin activity was initially pathologically low. During treatment it rose to supraphysiological levels. Also the radioimmunologically assayed somatomedin and the alkaline phosphatase increased significantly.</li><li>4.At the start of the first series, two patients showed allergic skin reactions which turned out to be caused by the insufficiently purified preparations. Therapy with extractive preparations was free of such side-effects and fully successful. Both of the patients were atopic. A third child who was also allergic developed after 6–9 months the highest antibody titres seen, combined with a high binding capacity. Also, with this boy, treatment was switched over to pit-hGH, with very good results.</li><li>5.Two children with pituitary dwarfism already developed in utero high antibody titres against Met-hGH but not against ECP. For this response, neither the Somatonorm nor its impurities can be implicated. Rather, it is the reaction to GH generally, which the organism recognizes as a foreign protein and thus as an antigen. One of the patients stopped growing after nine months. Likewise, pituitary GH did not lead to any further improvement.</li></ul></div>","PeriodicalId":10454,"journal":{"name":"Clinics in Endocrinology and Metabolism","volume":"15 3","pages":"Pages 511-535"},"PeriodicalIF":0.0,"publicationDate":"1986-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0300-595X(86)80009-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13576909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 35

Growth disorders. 增长的障碍。

Clinics in Endocrinology and Metabolism Pub Date : 1986-08-01

引用次数: 0

6 Growth hormone neurosecretory dysfunction 6生长激素神经分泌功能障碍

Clinics in Endocrinology and Metabolism Pub Date : 1986-08-01 DOI: 10.1016/S0300-595X(86)80010-X

Barry B. Bercu, Frank B. Diamond Jr

引用次数: 133